Who are Ibandronate+alfacalcidol+calcium's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibandronate-alfacalcidol-calcium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ibandronate+alfacalcidol+calcium — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ibandronate+alfacalcidol+calcium (Ibandronate+alfacalcidol+calcium) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate + active vitamin D + mineral supplement combination. Area: Bone metabolism / Osteoporosis.

marketed Bisphosphonate + active vitamin D + mineral supplement combination Farnesyl pyrophosphate synthase (ibandronate); vitamin D receptor (alfacalcidol); calcium channels (calcium) Bone metabolism / Osteoporosis Small molecule Live · refreshed every 30 min

Target snapshot

Ibandronate+alfacalcidol+calcium (Ibandronate+alfacalcidol+calcium) — Chinese University of Hong Kong. This combination therapy inhibits bone resorption via bisphosphonate action while simultaneously promoting bone mineralization through active vitamin D and calcium supplementation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ibandronate+alfacalcidol+calcium TARGET	Ibandronate+alfacalcidol+calcium	Chinese University of Hong Kong	marketed	Bisphosphonate + active vitamin D + mineral supplement combination	Farnesyl pyrophosphate synthase (ibandronate); vitamin D receptor (alfacalcidol); calcium channels (calcium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate + active vitamin D + mineral supplement combination class)

Chinese University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ibandronate+alfacalcidol+calcium — Competitive Intelligence Brief. https://druglandscape.com/ci/ibandronate-alfacalcidol-calcium. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab